238 related articles for article (PubMed ID: 8470344)
21. Artemisone inhibits in vitro and in vivo propagation of Babesia bovis and B. bigemina parasites.
Mazuz ML; Golenser J; Fish L; Haynes RK; Wollkomirsky R; Leibovich B; Shkap V
Exp Parasitol; 2013 Dec; 135(4):690-4. PubMed ID: 24184077
[TBL] [Abstract][Full Text] [Related]
22. Immunization of cattle with an inactivated polyvalent vaccine against anaplasmosis and babesiosis.
Montenegro-James S; Toro M; Leon E; Guillen AT; Lopez R; Lopez W
Ann N Y Acad Sci; 1992 Jun; 653():112-21. PubMed ID: 1626861
[No Abstract] [Full Text] [Related]
23. Bovine babesiosis: failure to induce interferon gamma production in response to Babesia bovis antigens in cattle.
Orinda GO; Gale KR; Wright IG; Parrodi F
Int J Parasitol; 1992 May; 22(3):395-8. PubMed ID: 1639576
[TBL] [Abstract][Full Text] [Related]
24. Viability after thawing and dilution of simultaneously cryopreserved vaccinal Babesia bovis and Babesia bigemina strains cultured in vitro.
Mangold AJ; Vanzini VR; Echaide IE; de Echaide ST; Volpogni MM; Guglielmone AA
Vet Parasitol; 1996 Feb; 61(3-4):345-8. PubMed ID: 8720572
[TBL] [Abstract][Full Text] [Related]
25. Prospects for recombinant vaccines against Babesia bovis and related parasites.
Brown WC; Norimine J; Goff WL; Suarez CE; McElwain TF
Parasite Immunol; 2006 Jul; 28(7):315-27. PubMed ID: 16842268
[TBL] [Abstract][Full Text] [Related]
26. Serological evidence of exposure to tick fever organisms in young cattle on Queensland dairy farms.
Sserugga JN; Jonsson NN; Bock RE; More SJ
Aust Vet J; 2003 Mar; 81(3):147-52. PubMed ID: 15080428
[TBL] [Abstract][Full Text] [Related]
27. Potential for recombinant Babesia bovis antigens to protect against a highly virulent isolate.
Hope M; Riding G; Menzies M; Colditz I; Reverter A; Willadsen P
Parasite Immunol; 2005 Dec; 27(12):439-45. PubMed ID: 16255742
[TBL] [Abstract][Full Text] [Related]
28. Stimulation of T-helper cell gamma interferon and immunoglobulin G responses specific for Babesia bovis rhoptry-associated protein 1 (RAP-1) or a RAP-1 protein lacking the carboxy-terminal repeat region is insufficient to provide protective immunity against virulent B. bovis challenge.
Norimine J; Mosqueda J; Suarez C; Palmer GH; McElwain TF; Mbassa G; Brown WC
Infect Immun; 2003 Sep; 71(9):5021-32. PubMed ID: 12933845
[TBL] [Abstract][Full Text] [Related]
29. Molecular approaches to elucidating innate and acquired immune responses to Babesia bovis, a protozoan parasite that causes persistent infection.
Brown WC
Vet Parasitol; 2001 Nov; 101(3-4):233-48. PubMed ID: 11707299
[TBL] [Abstract][Full Text] [Related]
30. Overcoming constraints to meeting increased demand for Babesia bigemina vaccine in Australia.
Standfast NF; Bock RE; Wiecek MM; deVos AJ; Jorgensen WK; Kingston TG
Vet Parasitol; 2003 Jul; 115(3):213-22. PubMed ID: 12935736
[TBL] [Abstract][Full Text] [Related]
31. An immunisation trial with in vitro produced Babesia bigemina exoantigens.
Beniwal RP; Nichani AK; Rakha NK; Sharma RD; Sarup S
Trop Anim Health Prod; 1997 Nov; 29(4 Suppl):124S-126S. PubMed ID: 9512758
[TBL] [Abstract][Full Text] [Related]
32. Development of a Babesia bovis live attenuated vaccine.
Alonso M; Blandino T; Mendoza E; Savon L; Camacho M
Arch Med Res; 1994; 25(2):273-7. PubMed ID: 7919825
[TBL] [Abstract][Full Text] [Related]
33. Babesial antibody dynamics after cattle immunisation with live vaccines, measured with an indirect immunofluorescence test.
Guglielmone AA; Lugaresi CI; Volpogni MM; Anziani OS; Vanzini VR
Vet Parasitol; 1997 Jun; 70(1-3):33-9. PubMed ID: 9195707
[TBL] [Abstract][Full Text] [Related]
34. Attenuated trivalent vaccine against babesiosis and anaplasmosis in Colombia.
Benavides E; Vizcaino O; Britto CM; Romero A; Rubio A
Ann N Y Acad Sci; 2000; 916():613-6. PubMed ID: 11193685
[No Abstract] [Full Text] [Related]
35. Field observations on the duration of immunity in cattle after vaccination against Anaplasma and Babesia species.
Tjornehoj K; Lawrence JA; Whiteland AP; Kafuwa PT
Onderstepoort J Vet Res; 1996 Mar; 63(1):1-5. PubMed ID: 8848296
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of South African Babesia bovis vaccine against field isolates.
Troskie PC; Latif AA; Mans BJ; Combrink MP
Ticks Tick Borne Dis; 2017 Jun; 8(4):671-674. PubMed ID: 28499721
[TBL] [Abstract][Full Text] [Related]
37. Assessment of Babesia bovis 6cys A and 6cys B as components of transmission blocking vaccines for babesiosis.
Alzan HF; Bastos RG; Ueti MW; Laughery JM; Rathinasamy VA; Cooke BM; Suarez CE
Parasit Vectors; 2021 Apr; 14(1):210. PubMed ID: 33879245
[TBL] [Abstract][Full Text] [Related]
38. The development of a recombinant Babesia vaccine.
Wright IG; Casu R; Commins MA; Dalrymple BP; Gale KR; Goodger BV; Riddles PW; Waltisbuhl DJ; Abetz I; Berrie DA
Vet Parasitol; 1992 Sep; 44(1-2):3-13. PubMed ID: 1441189
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the infectivity of a vaccinal and a pathogenic Babesia bovis strain from Argentina to Boophilus microplus.
Mangold AJ; Aguirre DH; Cafrune MM; de Echaide ST; Guglielmone AA
Vet Parasitol; 1993 Dec; 51(1-2):143-8. PubMed ID: 8128578
[TBL] [Abstract][Full Text] [Related]
40. The safety and efficacy of Australian tick-borne disease vaccine strains in cattle in Paraguay.
Brizuela CM; Ortellado CA; Sanabria E; Torres O; Ortigosa D
Vet Parasitol; 1998 Mar; 76(1-2):27-41. PubMed ID: 9653988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
